A detailed history of Raleigh Capital Management Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 42,480 shares of BMY stock, worth $2.5 Million. This represents 0.86% of its overall portfolio holdings.

Number of Shares
42,480
Previous 29,775 42.67%
Holding current value
$2.5 Million
Previous $1.24 Million 77.83%
% of portfolio
0.86%
Previous 0.53%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$39.66 - $51.75 $503,880 - $657,483
12,705 Added 42.67%
42,480 $2.2 Million
Q2 2024

Jul 31, 2024

BUY
$40.25 - $52.99 $137,896 - $181,543
3,426 Added 13.0%
29,775 $1.24 Million
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $1.07 Million - $1.22 Million
22,383 Added 564.37%
26,349 $1.43 Million
Q4 2023

Feb 21, 2024

BUY
$48.48 - $57.85 $125,078 - $149,253
2,580 Added 186.15%
3,966 $203,000
Q3 2023

Dec 06, 2023

SELL
$57.89 - $64.73 $616,296 - $689,115
-10,646 Reduced 88.48%
1,386 $80,000
Q2 2023

Jul 25, 2023

BUY
$63.71 - $70.74 $7,008 - $7,781
110 Added 0.92%
12,032 $769,000
Q1 2023

May 22, 2023

BUY
$65.71 - $74.53 $101,259 - $114,850
1,541 Added 14.84%
11,922 $826,000
Q4 2022

Feb 07, 2023

SELL
$68.48 - $81.09 $632,138 - $748,541
-9,231 Reduced 47.07%
10,381 $746,000
Q3 2022

Nov 09, 2022

SELL
$0.13 - $76.84 $254 - $150,145
-1,954 Reduced 9.06%
19,612 $1.39 Million
Q2 2022

Aug 30, 2022

SELL
$72.62 - $79.98 $30,137 - $33,191
-415 Reduced 1.89%
21,566 $1.66 Million
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $1.34 Million - $1.61 Million
21,862 Added 18371.43%
21,981 $1.61 Million
Q4 2021

Feb 16, 2022

BUY
$53.63 - $62.52 $6,381 - $7,439
119 New
119 $7,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Raleigh Capital Management Inc. Portfolio

Follow Raleigh Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raleigh Capital Management Inc. with notifications on news.